Claim Missing Document
Check
Articles

Found 2 Documents
Search

How do Different Surgical Techniques for Cataract Removal Impact Quality of Life And Functional Vision in Elderly Patients? : A Systematic Review Roysam Azmal sitanggang; Sita Pradjnadewi
The Indonesian Journal of General Medicine Vol. 13 No. 5 (2025): The Indonesian Journal of General Medicine
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/rxw4w903

Abstract

Introduction: Age-related cataracts significantly impair vision and diminish the quality of life in elderly individuals worldwide. Cataract surgery is the primary intervention to restore vision and improve daily functioning, but the variety of surgical techniques and intraocular lens (IOL) options necessitates understanding their impact on patient outcomes. This systematic review evaluates the impact of different cataract surgery techniques on the quality of life and functional vision of elderly patients, synthesizing evidence from recent clinical trials and observational studies to identify optimal surgical approaches. Methods: This systematic review adhered to the PRISMA 2020 guidelines. We included studies focusing on patients aged 60 and older with age-related cataracts, evaluating surgical techniques like phacoemulsification, MSICS, or ECCE. Eligible studies were primary research (RCT, cohort, case-control) or systematic reviews/meta-analyses, measuring both quality of life and functional vision outcomes with at least a 3-month follow-up. Data extraction by a large language model focused on study design, setting, participant demographics, surgical technique, and visual performance/quality of life outcomes. The search strategy utilized Boolean MeSH keywords across databases like PubMed, Semantic Scholar, Springer, and Google Scholar. Results: Out of 1538 initial records, 14 studies were included. Visual acuity improved in 13 out of 14 studies, with 10 showing statistically significant improvement. All 14 studies reported improved functional vision or patient-reported outcomes, with 10 achieving statistical significance. Six studies found significant quality of life improvement after intervention. Comparisons revealed no significant difference between femtosecond laser-assisted and standard phacoemulsification, while multifocal/trifocal IOLs improved intermediate/near vision but increased dysphotopsia. Second eye surgery showed additional gains. MSICS was found to be cost-effective with comparable outcomes to phacoemulsification in resource-limited settings. Active-fluidics systems may offer faster early recovery. Discussion: The studies consistently show significant improvements in visual function and quality of life across various cataract surgery techniques, including phacoemulsification and MSICS. Second eye surgery further amplifies these benefits, encompassing socioemotional well-being. While advanced technologies like femtosecond laser-assisted phacoemulsification offer precision, they may not yield significantly better clinical or quality of life results compared to standard methods. The choice of IOL significantly impacts vision, with multifocal and trifocal lenses improving intermediate and near vision but potentially increasing dysphotopsia. MSICS provides a cost-effective alternative in certain settings , and active-fluidics systems may enhance early recovery. Patient-reported outcomes are crucial for capturing the real-world impact of surgery. Conclusion: Cataract surgery is highly effective in restoring vision and enhancing quality of life for elderly patients, with consistent improvements across various techniques. Phacoemulsification remains widely adopted, and advanced IOLs expand visual optimization. Bilateral surgery maximizes functional and emotional gains. Cost-effectiveness of MSICS and the promise of emerging technologies like active-fluidics systems underscore the need for individualized care based on patient needs, cost, and potential side effects.
What are the most effective medical interventions for managing retinopathy of prematurity in preterm infants born ? : A Systematic Review Roysam Azmal sitanggang; Sita Pradjnadewi
The International Journal of Medical Science and Health Research Vol. 14 No. 3 (2025): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/xcyxt302

Abstract

Introduction: Retinopathy of Prematurity (ROP) is a leading cause of preventable childhood blindness affecting preterm infants. Laser photocoagulation, the traditional standard of care, is effective but inherently destructive, leading to permanent peripheral visual field defects and a high incidence of myopia. The introduction of anti-Vascular Endothelial Growth Factor (VEGF) agents like bevacizumab offers a less destructive approach with the potential for better refractive outcomes. However, concerns regarding disease recurrence and potential systemic effects persist. This systematic review was conducted to evaluate and synthesize current evidence to determine the most effective medical interventions for ROP. Methods: This systematic review adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. A comprehensive search was performed across PubMed, Semantic Scholar, Springer, and Google Scholar. Twenty-seven studies, including randomized controlled trials and comparative studies evaluating anti-VEGF therapies and laser photocoagulation, were included. The primary outcomes analyzed were disease regression, recurrence rates, and long-term structural and refractive outcomes. Results: The evidence consistently showed that both anti-VEGF therapy and laser photocoagulation are highly effective in achieving initial disease regression. A significant advantage for anti-VEGF therapy is more favorable long-term refractive outcomes, particularly a significantly lower incidence of high myopia compared to laser. However, this is counterbalanced by a variable but significant risk of disease recurrence following anti-VEGF monotherapy, a risk that is lower with laser treatment. Evidence also suggests clinical differences between agents, with one study finding a lower recurrence rate for bevacizumab compared to aflibercept. Conclusion: The optimal management for ROP requires balancing significant trade-offs. Anti-VEGF therapy is often the superior choice for posterior disease (Zone I) and offers the compelling benefit of better long-term vision by reducing high myopia. Conversely, laser photocoagulation provides a more definitive treatment with lower recurrence rates but at the known cost of peripheral vision. Combination strategies are emerging to leverage the strengths of both modalities. Ultimately, the treatment decision must be individualized, weighing the risk of recurrence and unknown systemic effects of anti-VEGF against the certainty of peripheral field loss and myopia from laser.